دورية أكاديمية

Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors.

التفاصيل البيبلوغرافية
العنوان: Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors.
المؤلفون: Moret-Tatay, Inés, Díaz, Joaquín, Marco, Francisco M, Crespo, Antonio, Aliño, Salvador F.
المصدر: Cancer Gene Therapy; Dec2003, Vol. 10 Issue 12, p887-897, 11p
مصطلحات موضوعية: VACCINES, CYTOKINES, TUMORS, LIPIDS
مستخلص: We report that 100% mice survival after tumor challenge is achieved with cytokine-engineered cells employing nonviral lipoplexes and without using viral vectors. We describe this effect with cytokine-secreting tumor cell vaccines, based on cell clones or fresh transfected cells. Tumor cells were transfected with murine granulocyte-macrophage colony-stimulating factor (GM-CSF) or IL-4 plasmids employing the cationic lipid DOTAP, were irradiated (150?Gy) and kept frozen until use. The transfection efficacy was analyzed by qRT-PCR and flow cytometry. Vaccination induced potent antitumor rejection, resulting in 100% mice survival. Furthermore, the antitumor immunity was long lasting, since a two-fold survival delay was observed in mice after tumor rechallenge (6 months later). While cell clones secreting GM-CSF were the most effective in wild-type tumor cell rejection, little or no effect was observed with clones secreting IL-4. We found similar antitumor efficacy employing fresh transfected cells by nonviral procedures, demonstrating that cells genetically modified by nonviral vectors (both clones and fresh transfected cells) are a safe and efficient tool for antitumor vaccines. These vaccines allow us to achieve the highest antitumor efficacy based on nonviral gene therapy techniques. In addition, the vaccination success with fresh transfected cells simplifies the procedure and provides new insights into the clinical application of nonviral gene therapy procedures.Cancer Gene Therapy (2003) 10, 887-897. doi:10.1038/sj.cgt.7700646 [ABSTRACT FROM AUTHOR]
Copyright of Cancer Gene Therapy is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:09291903
DOI:10.1038/sj.cgt.7700646